Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Post-ASCO 2024 GU Cancer Highlights

Interactive webinar featuring presentations & discussions on selected abstracts from ASCO 2024
Chair: Professor Thomas Powles | Moderator: Professor Sumanta Pal
20 June | 10:00–12:00 CDT/ 16:00–18:00 BST/ 17:00–19:00 CEST


Draft Agenda

(subject to change)

Timings are in CDT

10:00–10:20 | Session 1: Updates in penile and prostate cancer
  • A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial – #5009: Fernando  Maluf
  • Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153) – #LBA5000: Christos Kyriakopoulos
  • CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer – #5001: TBC
  • Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore – #5008: TBC
10:20–10:40 | Panel discussion
10:40–11:00 | Session 2: Updates in bladder and kidney cancer
  • Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results – #LBA4517: Antonio Cigliola
  • Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial – #4509: Guru Sonpavde
  • Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial – #4504: TBC
  • Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC) – #4505: Brian Rini
11:00–11:20 | Panel discussion
11:20–11:35 | Session 3: Updates in EGFR mutated lung cancer EGFR-targeted therapies
  • Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC) – #4502: TBC
  • Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-naïve patients with metastatic castration-resistant prostate cancer (PSMAfore) – #5003: TBC
  • EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL) – #5005: Stephen Freedland
11:35–12:00 | Panel discussion
12:00 | End of webinar


This webinar is for HCPs and allied health professionals only. Please apply for registration and we’ll confirm your application once received.